Skip to main content
. 2022 Sep 6;13:4981. doi: 10.1038/s41467-022-32521-8

Fig. 1. Lactate augments antitumor immunity through CD8+ T cells.

Fig. 1

a Treatment regimen for glucose (Glc) or lactate (Lac). Glucose (5 g/kg) or lactate (1.68 g/kg) was subcutaneously administrated daily from Day 8 after tumor inoculation. b Tumor growth curve of MC38 tumor model treated with glucose or lactate. C57BL/6 mice (n = 6) were inoculated with 1 × 106 MC38 tumor cells and treated with glucose or lactate. c, Tumor growth curves of MC38 tumor in B6.129S7-Rag1tm1Mom (Rag1−/−) mice treated with lactate. Rag1−/− mice (n = 7) were inoculated with 1 × 106 MC38 tumor cells and treated with lactate. CD8+ T cell (d), CD4+ T cell (e) and macrophage (f) depletion assay in MC38 tumor model. C57BL/6 mice (n = 6) were inoculated with 1 × 106 MC38 tumor cells and treated with lactate. Anti-CD8 (10 mg/kg) was administered on day 6 and then every three days until the end of the experiment. Anti-CD4 (10 mg/kg) or anti-CSF1R (20 mg/kg) was administered on day 3 and then every three days until the end of the experiment. Data are shown as means ± SEM. P value was determined by one-tail two-way ANOVA with correction using Geisser-Greenhouse method. Source data are provided in Source Data file.